Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK

BACKGROUND: Dupilumab, a monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signalling is indicated in dermatology for the treatment of moderate-to-severe atopic dermatitis (AD) in adult and adolescent patients 12 years and older and severe AD in children 6-11 yea...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Kane, D, Davis, L, Ardern-Jones, M, Laws, P, Shaw, L, Cork, M, Velangi, S, Cooper, HL, Hudson, R, Smith, AB, Rout, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Ulster Medical Society 2021
Materias:
Clinical Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278937/
https://www.ncbi.nlm.nih.gov/pubmed/34276083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278937/
https://www.ncbi.nlm.nih.gov/pubmed/34276083

Ejemplares similares